Targeted CRO Helix Biostructures operates as a structural biology CRO offering end-to-end gene-to-structure services including expression, purification, X-ray crystallography, Cryo-EM, Bio-SAXS, and biophysical characterization. This positions them to pursue partnerships with mid- to large-cap pharma and biotech companies seeking integrated drug discovery capabilities, especially those prioritizing structure-based design.

Small-to-Mid Cap Focus With a team size of 11-50 and revenue between 1M-10M, HBS is well suited for strategic collaborations with mid-sized biotech firms and startups needing flexible, cost-effective CRO services without large-entity overhead. This creates opportunities for sponsored programs, retainer arrangements, and milestone-based collaborations.

Collaborative Network A recent partnership with SilcsBio enhances the value proposition for customers seeking integrated software and services for structure-based drug design, suggesting sales opportunities in joint offerings, cross-referrals, and bundled solutions that combine computational design with experimental validation.

Global Reach Although based in Indianapolis, HBS serves the US and global drug discovery community, indicating potential sales prospects across geographies. Emphasize scalable, remote-enabled workflows and international project management to win global engagements.

Diversified Capabilities Service breadth spans protein expression, purification, crystallography, Cryo-EM, Micro-ED, Bio-SAXS, and multiple biophysical methods (ITC, SPR, MassSpec). This enables upsell opportunities to existing clients by expanding into additional structure determination techniques and orthogonal validation services as projects mature.